IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort.
Författare
Summary, in English
In breast cancer, high levels of the inflammatory cytokine interleukin-6 (IL-6) have been associated with disease-free survival and treatment resistance. Increased serum levels of IL-6 have been correlated with increased levels of NF-κβ and aromatase expression in adipose tissue. Several IL6 single nucleotide polymorphisms have been associated with breast cancer prognosis, but the impact may differ depending on tumour oestrogen receptor (ER) status. This translational study investigated the association between IL6 genotypes, ER-status, and treatment on the risk of early events among breast cancer patients.
Avdelning/ar
- Epidemiologi och farmakogenetik
- Bröstcancer-genetik
- Tumörmikromiljö
- Kirurgi, Lund
- BioCARE: Biomarkers in Cancer Medicine improving Health Care, Education and Innovation
Publiceringsår
2014
Språk
Engelska
Publikation/Tidskrift/Serie
BMC Cancer
Volym
14
Fulltext
Länkar
Dokumenttyp
Artikel i tidskrift
Förlag
BioMed Central (BMC)
Ämne
- Cancer and Oncology
Status
Published
Forskningsgrupp
- Epidemiology and pharmacogenetics
ISBN/ISSN/Övrigt
- ISSN: 1471-2407